Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
NBTX 
Nanobiotix (NBTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: NBTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -38.18% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 175.72M USD | Price to earnings Ratio - | 1Y Target Price 8.16 |
Price to earnings Ratio - | 1Y Target Price 8.16 | ||
Volume (30-day avg) 10936 | Beta 1.38 | 52 Weeks Range 2.76 - 7.51 | Updated Date 04/2/2025 |
52 Weeks Range 2.76 - 7.51 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.81 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -79.31% | Operating Margin (TTM) -253.32% |
Management Effectiveness
Return on Assets (TTM) -22.02% | Return on Equity (TTM) -198.69% |
Valuation
Trailing PE - | Forward PE 48.31 | Enterprise Value 150734543 | Price to Sales(TTM) 4.16 |
Enterprise Value 150734543 | Price to Sales(TTM) 4.16 | ||
Enterprise Value to Revenue 3.85 | Enterprise Value to EBITDA -2.45 | Shares Outstanding 47404700 | Shares Floating 25528397 |
Shares Outstanding 47404700 | Shares Floating 25528397 | ||
Percent Insiders - | Percent Institutions 12.79 |
Analyst Ratings
Rating 5 | Target Price 10.05 | Buy - | Strong Buy 3 |
Buy - | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Nanobiotix
Company Overview
History and Background
Nanobiotix was founded in 2003. It focuses on developing nanoparticle-based treatments for cancer, pioneering the field of physics-based cancer therapy. The company has advanced its lead product, NBTXR3, through clinical trials.
Core Business Areas
- Nanomedicine: Development and commercialization of nanoparticle-based cancer therapies.
- Oncology: Focus on treating various types of cancer, including head and neck cancers, soft tissue sarcomas, and liver cancers.
Leadership and Structure
Laurent Levy serves as the CEO. The company has a structured management team focused on R&D, clinical development, and commercialization.
Top Products and Market Share
Key Offerings
- NBTXR3 (Hensify): NBTXR3 is Nanobiotix's lead product, a radioenhancer designed to improve the effectiveness of radiotherapy. It's currently approved in Europe for soft tissue sarcoma. No established market share figures available due to the novel nature of the product and market access differences per country. Competitors include traditional radiotherapy methods and newer targeted therapies.
Market Dynamics
Industry Overview
The oncology market is large and growing, driven by aging populations and increasing cancer incidence. There's a growing demand for more effective and less toxic cancer treatments.
Positioning
Nanobiotix is positioned as an innovator in the field of physics-based cancer therapy. Its competitive advantage lies in its unique mechanism of action and potential to improve radiotherapy outcomes.
Total Addressable Market (TAM)
The TAM for cancer therapies is estimated to be in the hundreds of billions of dollars globally. Nanobiotix targets specific cancer types within this market, aiming to capture a share by improving the efficacy of existing radiotherapy treatments.
Upturn SWOT Analysis
Strengths
- Innovative technology platform
- Potential to improve radiotherapy outcomes
- Proprietary nanoparticle technology
- Experienced management team
- Approved product (Hensify) in Europe
Weaknesses
- Limited commercial infrastructure in the US
- Reliance on clinical trial success
- Cash burn and need for additional financing
- Concentration of product pipeline
- Competition from established cancer therapies
Opportunities
- Expansion into new cancer indications
- Partnerships with pharmaceutical companies
- FDA approval for NBTXR3 in the US
- Growing demand for precision cancer therapies
- Expansion to new geographies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established cancer therapies
- Pricing and reimbursement challenges
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- Varian Medical Systems (VAR)
- Elekta AB (EKTAY)
Competitive Landscape
Nanobiotix is a smaller player compared to established radiotherapy equipment manufacturers. Its advantage lies in its unique technology and potential to improve treatment outcomes. However, it faces challenges in competing with larger companies with greater resources and established market presence.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily driven by clinical development milestones and regulatory approvals.
Future Projections: Future growth depends on the successful commercialization of NBTXR3 and expansion into new indications. Analyst estimates are variable.
Recent Initiatives: Recent initiatives include advancing clinical trials in head and neck cancers and exploring combination therapies.
Summary
Nanobiotix is an innovative company with a promising technology in NBTXR3, however, its success hinges on future trial data and market adoption. The company needs to successfully navigate regulatory hurdles and compete with established players. Its financial stability remains a concern, requiring continued financing. Recent clinical progress in various cancer types offers hope for the future.
Similar Companies
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
MRK
Merck & Company Inc
MRK
Merck & Company Inc
Sources and Disclaimers
Data Sources:
- Nanobiotix Investor Relations
- Company SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated and may not be precise. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nanobiotix
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-12-11 | Co-Founder, President of the Executive Board & CEO Mr. Laurent Levy Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 110 | Website https://www.nanobiotix.com |
Full time employees 110 | Website https://www.nanobiotix.com | ||
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.